Literature DB >> 11890589

Advancing age and cervical cancer screening and prognosis.

G F Sawaya1, H Y Sung, K A Kearney, M Miller, W Kinney, R A Hiatt, J Mandelblatt.   

Abstract

OBJECTIVES: To determine associations between advancing age and screening behavior and prognosis in long-term members of a prepaid health plan diagnosed with invasive cervical cancer (ICC).
DESIGN: Case series.
SETTING: Prepaid health plan. PARTICIPANTS: All women diagnosed with ICC at Kaiser Permanente Medical Care Program-Northern California health plan from 1988 to 1994. MEASUREMENTS: From medical records, we recorded participants' age, stage at diagnosis, tumor histology, and results of and reasons for all previous cervical smears. We limited our analysis to women who had been members of the health plan for at least 30 of the 36 months preceding diagnosis (n = 455).
RESULTS: Women in older age groups were less likely than younger women to have been screened within the 3 years before diagnosis (P = .005 for trend). Nonadherence to follow-up of abnormal cervical smears was uncommon (17/455, 3.7%) and not age related (P = .932 for trend). The proportions of ICC that were interval cancers, defined as ICC diagnosed within 3 years of a negative screening smear, were highest in women under age 30 (P = .004 for trend). In multivariate analyses controlling for stage at diagnosis, women age 60 and older were not more likely to die of ICC within 3 years of diagnosis than were women younger than age 60 (odds ratio 1.30, 95% confidence interval 0.75-2.28).
CONCLUSION: The disproportionate burden of cervical cancer observed in older women appears to be largely attributable to lack of screening within the 3 years before diagnosis.

Entities:  

Mesh:

Year:  2001        PMID: 11890589     DOI: 10.1046/j.1532-5415.2001.4911243.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  8 in total

1.  Making Sense of Cervical Cancer Screening Guidelines and Recommendations.

Authors:  Michelle Davis; Sarah Feldman
Journal:  Curr Treat Options Oncol       Date:  2015-12

2.  Invasive cervical cancer and screening: what are the rates of unscreened and underscreened women in the modern era?

Authors:  Akila Subramaniam; Janelle M Fauci; Kellie E Schneider; Jenny M Whitworth; Britt K Erickson; Kenneth Kim; Warner K Huh
Journal:  J Low Genit Tract Dis       Date:  2011-04       Impact factor: 1.925

3.  The changing face of cervical cancer screening in the United States.

Authors:  Warner K Huh
Journal:  J Natl Compr Canc Netw       Date:  2010-12       Impact factor: 11.908

4.  Medicaid status and stage at diagnosis of cervical cancer.

Authors:  Cynthia D O'Malley; Sarah J Shema; Lisa S Clarke; Christina A Clarke; Carin I Perkins
Journal:  Am J Public Health       Date:  2006-10-31       Impact factor: 9.308

5.  Effectiveness of screening for cervical cancer in an inpatient hospital setting.

Authors:  Cornelia L Trimble; Lynn A Richards; Barbara Wilgus-Wegweiser; Karen Plowden; Dorothy L Rosenthal; Ann Klassen
Journal:  Obstet Gynecol       Date:  2004-02       Impact factor: 7.661

6.  Understanding cervical cancer after the age of routine screening: Characteristics of cases, treatment, and survival in the United States.

Authors:  Katie E Lichter; Kimberly Levinson; Anne Hammer; Melissa H Lippitt; Anne F Rositch
Journal:  Gynecol Oncol       Date:  2022-02-01       Impact factor: 5.482

7.  Cervical Cancer Screening Service Uptake and Associated Factors among Age Eligible Women in Mekelle Zone, Northern Ethiopia, 2015: A Community Based Study Using Health Belief Model.

Authors:  Hinsermu Bayu; Yibrah Berhe; Amlaku Mulat; Amare Alemu
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

8.  Comprehensive knowledge and uptake of cervical cancer screening is low among women living with HIV/AIDS in Northwest Ethiopia.

Authors:  Daniel Asfaw Erku; Adeladlew Kassie Netere; Amanual Getnet Mersha; Sileshi Ayele Abebe; Abebe Basazn Mekuria; Sewunet Admasu Belachew
Journal:  Gynecol Oncol Res Pract       Date:  2017-12-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.